A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients

Current Medical Research and Opinion
Gregory BellGeoffrey A Block

Abstract

Secondary hyperparathyroidism (SHPT) is a frequent complication of chronic kidney disease. We evaluated AMG 416, a long-acting peptide agonist of the calcium-sensing receptor, to assess its safety, tolerability, and efficacy and to determine a safe and effective starting dose for subsequent phase 2 studies. The study was not designed to titrate AMG 416 dosing to achieve a specific PTH treatment goal. This is a multicenter, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate the safety and efficacy of AMG 416 administered thrice weekly by IV bolus at the end of hemodialysis for up to 4 weeks. Eligible subjects were enrolled in one of three cohorts and treated with 5 mg of AMG 416 or placebo for 2 weeks (Cohort 1) or 5 or 10 mg of AMG 416 or placebo for 4 weeks (Cohorts 2 and 3). The primary endpoint was mean percentage change from baseline in PTH during the efficacy assessment phase (EAP) in Cohorts 2 and 3. Analysis of the primary endpoint showed that treatment with AMG 416 at 10 mg (Cohort 2) and 5 mg (Cohort 3) for up to 4 weeks resulted in mean 49.4% and 33.0% reductions from baseline in PTH during the efficacy assessment phase, respectively (p < 0.05 for both cohorts compared to placebo ...Continue Reading

References

Jul 8, 2000·Kidney International·A M AlemC Stehman-Breen
Apr 12, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·P T DonnanA D Morris
Jun 26, 2002·Kidney International·Glenn M ChertowUNKNOWN Treat to Goal Working Group
Nov 1, 2003·The Journal of Pharmacology and Experimental Therapeutics·Edward F NemethDavid Martin
Apr 7, 2004·Clinical and Experimental Nephrology·Mitsuteru MatsuokaShuichi Takishita
Apr 9, 2004·The New England Journal of Medicine·Geoffrey A BlockWilliam G Goodman
Jul 31, 2004·Journal of the American Society of Nephrology : JASN·Geoffrey A BlockGlenn M Chertow
Jul 28, 2007·Journal of the American Society of Nephrology : JASN·Danilo FliserPeter Riegler
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Aug 9, 2008·The New England Journal of Medicine·Orlando M GutiérrezMyles Wolf
Oct 4, 2008·The Journal of International Medical Research·X LiuS Liu
Oct 15, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Guillaume JeanCharles Chazot
Feb 24, 2009·Current Medical Research and Opinion·Debora Williams-HermanJohn M Amatruda
Dec 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·James B WetmoreL Darryl Quarles
Aug 28, 2010·European Journal of Heart Failure·Emil HagströmJohan Arnlöv
Apr 2, 2011·Clinical Journal of the American Society of Nephrology : CJASN·John CunninghamMariano Rodriguez
Jul 7, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Masahiro KoizumiMasafumi Fukagawa
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Oct 12, 2011·The Journal of Clinical Investigation·Christian FaulMyles Wolf
Jun 12, 2012·The Journal of Clinical Endocrinology and Metabolism·Elza MuscelliEle Ferrannini
Nov 28, 2012·Therapeutic Advances in Endocrinology and Metabolism·Janet B McGill
Jun 12, 2013·Postgraduate Medicine·George Grunberger
Jul 3, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberMichael H Davidson

❮ Previous
Next ❯

Citations

Sep 1, 2015·Calcified Tissue International·E F Nemeth, W G Goodman
Jun 9, 2016·Clinical Journal of the American Society of Nephrology : CJASN·James B Wetmore
Jun 9, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Sun Moon KimGlenn M Chertow
Oct 21, 2015·Trends in Molecular Medicine·Punita KumariArun K Shukla
Dec 3, 2016·Drugs·Hannah A Blair
Mar 10, 2017·Expert Opinion on Pharmacotherapy·Naoto HamanoMasafumi Fukagawa
Apr 6, 2017·Reviews in Endocrine & Metabolic Disorders·Mariano Rodríguez Portillo, María E Rodríguez-Ortiz
Dec 26, 2017·Hospital Pharmacy·Danial E Baker
Jan 20, 2016·Current Opinion in Nephrology and Hypertension·Andrew L Lundquist, Sagar U Nigwekar
Dec 27, 2016·Frontiers in Physiology·Arthur D Conigrave
Jan 7, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Masafumi FukagawaUNKNOWN ONO-5163 Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.